The U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) as a preventative measure against potential pulmonary embolism-causing blood clots for patients who have undergone hip or knee replacement therapy, according to a news release.
Previously, Eliquis was only approved to reduce the risk of stroke and blood clots for patients with atrial fibrilliation not caused by a heart valve problem.
More Articles on FDA Approvals:
FDA Approves Migraine 'Headband' for Marketing
FDA Approves Myalept to Treat Lipodystrophy Complications
Medtronic Receives FDA 510(k) Clearance for Reveal LINQ Insertable Cardiac Monitor